GLP-1 drugs linked to up to 68% higher risk of hair loss, study finds |
People taking GLP-1 medications for type 2 diabetes had a substantially higher rate of clinically recorded hair loss than those on two alternative treatments, according to a new study.
Compared with people taking SGLT-2 inhibitors, GLP-1 users had a 37% higher chance of developing non-scarring alopecia, a type of hair loss that doesn't permanently damage the follicle. Against DPP-4 inhibitors, the increased risk climbed to 68%.
The absolute numbers are small, with only about 6-7 cases per 1,000 GLP-1 users each year. But the researchers say the pattern held closely enough across both comparisons to be worth flagging to patients before they start treatment.
“The medication acts as a catalyst for weight loss, but the resulting physiological stress and hormonal changes are often the direct trigger,” said Mir Ali, MD, a bariatric surgeon not involved in the study.
Researchers now want to know whether the risk tracks with how fast someone loses weight, or with specific nutritional shortfalls along the way.
To learn more about the risk of hair loss with GLP-1s, jump to “GLP-1 drugs linked to temporary hair loss: Here’s why.”
Also making headlines this week:
| |
